Vasculitis Activity (BVAS) Score protein (CRP) level, ANCA level or Birmingham compared to the original Vasculitis Activity (BVAS) Score or other indicator qualifying value. of active disease compared to the previous review score AND On review of a continuing authorisation period A trial off Ig therapy is planned following two Once the patient has been in years in remission unless a valid reason is clinical remission for two years, a provided trial off therapy should be considered. Patients demonstrate evidence of clinical benefit and response to Ig treatment as assessed by stabilisation of at least one indicator of Erythrocyte Sedimentation Rate (ESR), C-reactive protein (CRP) level, ANCA level or Birmingham Vasculitis Activity (BVAS) Score compared to the previous review score AND A trial off Ig therapy is planned unless a valid reason is provided.
Vasculitis Activity (BVAS) Score compared to the original qualifying value. On review of a continuing authorisation period Once the patient has been in clinical remission for two years, a trial off therapy should be considered. Patients demonstrate evidence of clinical benefit and response to Ig treatment as assessed by stabilisation of at least one indicator of Erythrocyte Sedimentation Rate (ESR), C-reactive protein (CRP) level, ANCA level or Birmingham Vasculitis Activity (BVAS) Score compared to the previous review score AND A trial off Ig therapy is planned unless a valid reason is provided. protein (CRP) level, ANCA level or Birmingham Vasculitis Activity (BVAS) Score or other indicator of active disease compared to the previous review score AND A trial off Ig therapy is planned following two years in remission unless a valid reason is provided
Immunology-Ch6-Anti-neutrophil-cytoplasmic-antibody-%28ANCA%29.DOCX